Last updated: August 17, 2026
Cardene I.V. in 4.8% Dextrose Injection is an established hospital injectable containing nicardipine hydrochloride, a short-acting intravenous calcium-channel blocker used to control blood pressure when oral therapy is not practical. Its commercial position is mature and primarily shaped by generic competition, hospital contracting, supply reliability and acute-care demand. Patent exclusivity is no longer the primary barrier to entry, and product-level revenue is not publicly disclosed.
What is Cardene in 4.8% Dextrose?
Cardene I.V. in 4.8% Dextrose is a premixed intravenous formulation of nicardipine hydrochloride supplied in a plastic container. It is administered by continuous intravenous infusion and is used for short-term treatment of hypertension in clinical settings.
| Attribute |
Product profile |
| Brand |
Cardene I.V. |
| Active ingredient |
Nicardipine hydrochloride |
| Drug class |
Dihydropyridine calcium-channel blocker |
| Route |
Intravenous infusion |
| Container |
Plastic flexible container |
| Diluent |
4.8% dextrose injection |
| Primary setting |
Hospitals, intensive-care units, emergency departments and perioperative care |
| Main use |
Short-term blood-pressure control |
| Regulatory pathway |
Original new drug application, followed by generic ANDA competition |
| Biosimilar exposure |
None; nicardipine is a small-molecule drug |
| Commercial maturity |
Mature, multisource injectable market |
The formulation competes with nicardipine injection products supplied in other diluents, including sodium chloride, as well as pharmacy-compounded preparations. The dextrose presentation has value where hospitals prefer a ready-to-administer product or where the clinical protocol permits dextrose as the infusion vehicle.
What is the FDA status of Cardene I.V. in 4.8% Dextrose?
The FDA approved Cardene I.V. as an intravenous nicardipine product for short-term treatment of hypertension when oral therapy is not feasible or desirable. The label includes dosing, infusion administration, monitoring and warnings concerning hypotension, tachycardia and administration through appropriate intravenous access.[1]
The product is an established prescription injectable rather than a recently launched specialty medicine. Its commercial lifecycle is therefore driven by hospital formulary placement and supply performance rather than by expanding exclusivity.
The relevant regulatory issues include:
- Continued maintenance of the approved NDA.
- Manufacturing compliance for sterile injectable production.
- Container-closure integrity.
- Stability of the dextrose formulation.
- Accurate labeling of concentration and infusion instructions.
- FDA approval of competing generic ANDAs.
- Potential drug-shortage reporting and allocation activity.
The product has no biosimilar pathway because nicardipine hydrochloride is a chemically synthesized small molecule. Competitors enter through the abbreviated new drug application pathway, generally demonstrating pharmaceutical equivalence and bioequivalence rather than conducting a biosimilar comparability program.
What is the Orange Book status of Cardene in 4.8% Dextrose?
Cardene’s original market protection has expired. The product was first approved decades ago, and any original composition, use or formulation patents would have reached the end of their ordinary patent terms before the current mature-market period.
The commercial question is not whether Cardene retains original exclusivity. It does not. The relevant question is whether any current patent listing, regulatory exclusivity or product-specific barrier limits generic substitution. For a legacy nicardipine injectable, the principal barriers are manufacturing and market access rather than patent duration.
| Protection category |
Current commercial relevance |
| New chemical entity exclusivity |
Expired |
| Original compound patents |
Expired |
| Pediatric exclusivity |
No material current impact expected |
| Orphan-drug exclusivity |
Not applicable |
| Biologic exclusivity |
Not applicable |
| Orange Book patent protection |
Not the principal barrier to entry |
| Formulation differentiation |
Commercially relevant, but generally weaker than active-ingredient exclusivity |
| Sterile manufacturing capability |
High practical importance |
| Hospital contracting |
High importance |
| Supply history |
High importance |
An Orange Book listing can be relevant to a specific NDA presentation, but an old injectable brand should not be valued as though it has a live composition-of-matter patent. Generic applicants can challenge any listed patent through Paragraph IV certification, but the absence of meaningful remaining patent life reduces the litigation value of such challenges.
When did Cardene lose exclusivity?
Cardene lost the economic effect of its original exclusivity years ago. The active ingredient, nicardipine, is a mature antihypertensive molecule, and generic injectable versions have been marketed for many years.
The timing has three commercial consequences:
- The branded product cannot rely on premium pricing protected by patent exclusivity.
- Hospitals can source equivalent nicardipine injection products from multiple suppliers.
- Revenue depends on retention, availability and contracting rather than on new-patient exclusivity.
The exact end date of every historical patent is less important to current valuation than the present multisource status of the product. For investment and licensing analysis, Cardene should be modeled as a mature injectable asset with limited patent-based pricing power.
How many patents cover Cardene in 4.8% Dextrose?
No meaningful current patent estate is publicly associated with Cardene’s commercial position. The original nicardipine patent portfolio is historical. Any residual formulation or manufacturing patents would need to be assessed claim by claim, including their expiration status, Orange Book listing and relevance to the exact 4.8% dextrose presentation.
The product’s protection profile is best characterized as follows:
| Patent issue |
Assessment |
| Active ingredient patent |
Expired |
| Core therapeutic-use patent |
Expired or commercially immaterial |
| Premixed dextrose formulation |
Potentially differentiated, but not normally equivalent to active-ingredient exclusivity |
| Plastic-container technology |
Usually dependent on supplier and manufacturing know-how |
| Manufacturing process |
May create operational barriers without preventing generic substitution |
| Current Paragraph IV threat |
Possible in theory, but not the central commercial risk |
| Patent-based price premium |
Low |
A formulation patent could protect a specific concentration, diluent, container or stability profile. That protection would not automatically prevent competitors from marketing nicardipine in another compatible diluent or from obtaining approval for an alternative presentation.
Which companies challenge Cardene with generic products?
Generic competition comes from manufacturers of nicardipine hydrochloride injection and premixed intravenous products. The relevant competitive field can include:
- Generic injectable manufacturers with FDA-approved ANDAs.
- Contract manufacturers supplying hospital distributors.
- Specialty injectable companies focused on shortage-prone products.
- Hospital pharmacies that compound or prepare diluted nicardipine solutions.
- Wholesalers and group purchasing organization suppliers.
The precise supplier set changes over time because sterile injectable manufacturers enter, exit, transfer applications or experience temporary supply interruptions. In this market, a company may be an approved ANDA holder, a contract manufacturer, a labeler or a distributor without being the underlying producer.
The main competitive variables are:
- Approved concentration and presentation.
- Dextrose versus sodium-chloride diluent.
- Ready-to-use versus pharmacy-prepared product.
- Container size.
- Shelf life.
- Cold-chain or room-temperature handling.
- Fill-finish capacity.
- National distribution.
- Hospital contract status.
- Shortage history.
What formulations are protected or commercially differentiated?
The 4.8% dextrose presentation is a formulation and packaging differentiator rather than a new active ingredient. Its commercial value comes from reducing preparation steps and supporting standardized hospital administration.
Premixed intravenous formulation
A premixed product can reduce pharmacy labor, compounding risk and preparation time. Hospitals may prefer it for high-acuity use where dosing must begin quickly and standardized concentrations reduce calculation errors.
Dextrose vehicle
Dextrose provides an alternative to saline-based products. The choice can depend on institutional protocols, fluid-management considerations and compatibility requirements. The presence of dextrose does not by itself create durable market exclusivity.
Plastic container
The plastic container supports ready-to-use distribution and may simplify storage and administration. It also creates technical requirements related to drug-container interaction, extractables and leachables, oxygen permeability, particulate control and stability.
These attributes can differentiate the product in tenders and hospital formularies, but they do not normally support the economics of a patented specialty drug.
What is the market dynamic for Cardene?
Cardene operates in a narrow acute-care market. Demand is linked to episodes requiring rapid, titratable blood-pressure reduction, including:
- Hypertensive emergencies.
- Neurologic critical care.
- Intracranial hemorrhage and ischemic stroke protocols.
- Perioperative hypertension.
- Cardiovascular intensive care.
- Patients unable to receive oral antihypertensive therapy.
Demand is relatively defensive because these uses are tied to hospital acuity rather than elective prescription volume. The product is not exposed to the same refill-cycle economics as an oral chronic hypertension medicine.
The market is still price-sensitive. Hospitals and group purchasing organizations often evaluate injectable drugs through contract bids, multisource substitution and supply guarantees. A supplier with a small price advantage can gain volume, but a supplier with a shortage history can lose formulary confidence quickly.
The most important market forces are:
- Generic price erosion.
- Hospital purchasing consolidation.
- Ready-to-use product preference.
- Sterile injectable shortages.
- Supplier reliability.
- Nursing and pharmacy labor costs.
- Clinical protocols favoring titratable intravenous agents.
- Substitution with clevidipine, esmolol, labetalol or other intravenous antihypertensives.
How does Cardene compare with competing intravenous antihypertensives?
Cardene competes primarily on titratability, familiarity and availability. It is not the only intravenous agent used for acute blood-pressure management.
| Product |
Active ingredient |
Key competitive attribute |
Principal limitation |
| Cardene I.V. |
Nicardipine |
Established titratable calcium-channel blocker |
Generic price pressure and infusion monitoring |
| Generic nicardipine injection |
Nicardipine |
Lower-cost equivalent |
Supplier variability |
| Cleviprex |
Clevidipine |
Rapid titration and short half-life |
Higher cost and formulation-specific considerations |
| Labetalol injection |
Labetalol |
Broad hospital familiarity |
Less continuous titration flexibility in some settings |
| Esmolol injection |
Esmolol |
Very short acting beta-blocker |
Different pharmacologic profile |
| Nitroprusside |
Sodium nitroprusside |
Potent rapid vasodilation |
Monitoring and toxicity concerns |
| Hydralazine injection |
Hydralazine |
Low acquisition cost |
Less predictable response and titration |
Cardene’s strongest position is in protocols requiring continuous, titratable control without relying on an ultra-premium branded product. Cleviprex can capture use where rapid onset and offset justify a higher acquisition cost. Labetalol remains a major alternative where intermittent dosing is acceptable.
What generic entry risks exist?
Generic entry risk is already realized rather than prospective. The product is exposed to continuing multisource competition, additional ANDA approvals and substitution among equivalent presentations.
Further erosion could occur through:
- New premixed nicardipine products.
- Lower-cost generic bids.
- Hospital system standardization on a single supplier.
- Greater use of pharmacy-compounded solutions.
- Conversion from branded Cardene to generic nicardipine.
- Contract losses following supply interruptions.
The main constraint on additional generic entry is not patent litigation. It is the economics of sterile injectable manufacturing. A new entrant must validate aseptic processes, secure reliable active pharmaceutical ingredient supply, meet FDA manufacturing standards and obtain hospital distribution.
What patent litigation and Paragraph IV challenges affect Cardene?
No major ongoing patent-litigation thesis defines the Cardene market. The product’s historical patent protection is expired or commercially immaterial, and the market is characterized by generic substitution rather than active patent enforcement.
Paragraph IV litigation would matter only if a current Orange Book-listed patent covered the specific NDA presentation and retained enforceable life. In a legacy nicardipine injectable market, that condition is unlikely to be the central driver of valuation.
The more relevant legal and regulatory exposures are:
- ANDA approval disputes.
- FDA manufacturing warning letters or import restrictions.
- Product-liability claims.
- Labeling disputes.
- Supply and allocation contracts.
- Antitrust concerns involving hospital contracting.
- Patent disputes over a newly engineered premix or container system.
What is the financial trajectory of Cardene?
Cardene-specific revenue is not separately disclosed in the public financial reporting of its commercial owner. The product should therefore be modeled through market proxies rather than as a directly observable revenue line.
The financial trajectory is likely mature to declining in nominal brand terms, with possible stabilization in unit demand. The commercial pattern is:
| Period |
Financial profile |
| Original launch period |
Innovation and exclusivity-driven growth |
| Early generic period |
Rapid price and share pressure |
| Mature multisource period |
Lower prices, stable acute-care demand |
| Current phase |
Volume retention depends on supply, contracts and presentation |
| Long-term outlook |
Low growth, with upside from shortages or contract wins |
Revenue exposure is limited by four factors:
- The product is old and lacks meaningful exclusivity.
- Generic substitutes cap price.
- Hospital buyers exert purchasing pressure.
- Product-level revenue is not publicly reported.
Potential revenue support comes from:
- Continued use in neurocritical-care protocols.
- Demand for ready-to-use premixes.
- Temporary competitor shortages.
- Manufacturing or supply agreements.
- Retention of hospital contracts.
- Higher utilization of titratable intravenous antihypertensives.
Potential revenue erosion comes from:
- Brand-to-generic conversion.
- Contract rebidding.
- Competitor price cuts.
- Broader use of clevidipine or labetalol.
- Pharmacy compounding.
- Product discontinuation or supply interruptions.
The product’s value is more likely to reside in recurring institutional demand and manufacturing infrastructure than in patent-backed margin expansion.
How strong is the patent estate for Cardene?
The patent estate is weak as a current commercial asset. Cardene’s defensibility rests on execution rather than exclusivity.
| Strength category |
Rating |
Rationale |
| Composition-of-matter protection |
Low |
Historical protection expired |
| Regulatory exclusivity |
Low |
Mature product |
| Formulation differentiation |
Low to moderate |
Premix and diluent may support preference, not broad exclusion |
| Manufacturing barrier |
Moderate |
Sterile injectable production is technically demanding |
| Brand recognition |
Moderate |
Established hospital familiarity |
| Hospital switching costs |
Moderate |
Protocols and supplier qualification matter |
| Pricing power |
Low |
Generic and GPO pressure |
| Supply-based defensibility |
Moderate |
Reliable availability can support contracts |
| Long-term growth potential |
Low |
Mature acute-care category |
What licensing deals affect Cardene?
No major product-specific licensing transaction is central to the current Cardene investment case. The commercial arrangement may involve brand ownership, marketing rights, contract manufacturing or distribution agreements, but product-level terms are not publicly disclosed in a way that supports a reliable valuation.
Any licensing value would depend on:
- Geographic rights.
- NDA or ANDA ownership.
- Manufacturing control.
- Hospital-contract access.
- Shortage history.
- Rights to related nicardipine presentations.
- Minimum purchase obligations.
- Transferability of regulatory files.
A licensee should treat Cardene as a supply-chain and commercial execution asset, not as a patent-protected innovation asset.
What geographic coverage does Cardene have?
The strongest commercial relevance is in the United States, where Cardene I.V. is an established hospital product and the FDA-approved formulation supports institutional use. International markets may have separate nicardipine approvals, brand names, suppliers and patent histories.
Geographic value depends on:
- Local approval of the dextrose presentation.
- Hospital procurement systems.
- Generic substitution rules.
- Sterile manufacturing and import requirements.
- Local shortage conditions.
- Distribution rights.
- Reimbursement and tender pricing.
U.S. value should not be extrapolated directly to Europe, Japan or emerging markets because intravenous antihypertensive procurement is highly jurisdiction-specific.
Key Takeaways
- Cardene in 4.8% Dextrose is a mature nicardipine hydrochloride intravenous product for short-term blood-pressure control.
- Original compound and exclusivity protection are no longer commercially significant.
- The product faces generic and multisource competition rather than a pending first-wave generic threat.
- No biosimilar risk exists because nicardipine is a small molecule.
- The premixed dextrose formulation and plastic container create convenience and procurement differentiation, not durable monopoly protection.
- Sterile manufacturing, FDA compliance, supply reliability and hospital contracting are the principal barriers to competition.
- Cardene-specific revenue is not publicly disclosed.
- The likely financial profile is stable or declining unit economics, with upside from shortage events, ready-to-use demand and institutional contracts.
- Patent litigation and Paragraph IV activity are secondary to manufacturing and commercial execution.
- Long-term growth potential is low, but acute-care demand provides a recurring base.
FAQs
Is Cardene in 4.8% Dextrose the same as generic nicardipine?
It contains the same active ingredient, nicardipine hydrochloride, but presentations can differ in concentration, diluent, container, labeling and approved packaging. Substitution depends on FDA approval, hospital policy and pharmacy practice.
Can hospitals compound nicardipine instead of buying Cardene?
Hospitals may prepare nicardipine infusions under applicable pharmacy and compounding requirements. Ready-to-use products can remain attractive because they reduce preparation time and operational burden.
Does Cardene have exclusivity against generic nicardipine?
No meaningful original exclusivity remains. Generic nicardipine products compete in the market, subject to FDA approval and product-specific labeling.
Is the 4.8% dextrose formulation protected by a separate patent?
A formulation or container patent could exist for a particular presentation, but the commercial record does not support treating the product as protected by a current broad patent monopoly. Any asserted patent would require claim-level and Orange Book analysis.
What is the main investment risk for a Cardene supplier?
The main risk is margin and volume erosion from hospital contracting, generic competition and substitution. Operational risks include sterile manufacturing failures, FDA compliance actions and supply interruptions.
References
- U.S. Food and Drug Administration. (n.d.). Cardene I.V. (nicardipine hydrochloride) injection prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. National Library of Medicine. (n.d.). Cardene I.V. in dextrose injection: DailyMed drug label. https://dailymed.nlm.nih.gov/
- U.S. Food and Drug Administration. (n.d.). Approved drug products and abbreviated new drug applications. https://www.fda.gov/drugs/drug-approvals-and-databases
- U.S. Food and Drug Administration. (n.d.). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
